Return to Clinical Trials Search Results

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry

Primary: Create a large scale, population-based registry of full genome expression data matched with clinical data to investigate new gene associations with prognostic and/or predictive value Utilize registry data to graduate identified expression signatures into subset trials and recommend interventional trials Secondary: Generate hypothesis for targeted subset trials based on full genome data Measure the impact of assays on patient decisions and confidence Demonstrate prognostic and predictive efficacy in groups beyond those currently clinically indicated for MammaPrint and Blue Print Track changes in genomic signature through serial MammaPrint and Blue Print signatures in the neoadjuvant setting Determine prognostic and predictive power of MammPrint and BluePrint as measured by outcomes Validate MammaPrint and BluePrint reclassification of traditional clinicopathological subtypes Capture clinical outcomes in specific race and ethnicity groups to broaden relative genomic signature data Exploratory: Proof of concept for matching patients into early and/or late phase interventional trials based on baseline genomic signatures

Phase

Post-market

Recruitment Status

Current Studies